Abstracts tagged "psoriatic arthritis and ankylosing spondylitis (AS)"

Abstract Number: 616 • 2019 ACR/ARP Annual Meeting
Association of Clinical and Radiographic Phenotype of Axial Spondyloarthritis and Skin Psoriasis: Results from the German Spondyloarthritis Inception Cohort
Mikhail Protopopov¹, Fabian Proft ², Joachim Sieper ², Hildrun Haibel ², Martin Rudwaleit ³ and Denis Poddubnyy ⁴, ¹Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ³Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ⁴Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: Psoriasis is a common feature of axial spondyloarthritis (axSpA) occuring in approximately 10% of patients with axSpA. It has been presumed that such an…
Abstract Number: 1014 • 2019 ACR/ARP Annual Meeting
Regulatory Role of IL-23 and Its Receptor System in Spondyloarthritis and Its Therapeutic Relevance in anti-IL-17 Failure Patients
Siba Raychaudhuri¹ and Smritikana Raychaudhuri ², ¹UC Davis School of Medicine, Sacramento, CA, ²UC Davis School of Medicine, Davis, CA
Background/Purpose: Here we hypothesized that (i) IL-23/IL-23R system more specifically the specific IL-23p19 subunit mediated signaling system regulates expansion/maintenance and functional maturation in respect to…
Abstract Number: 2288 • 2019 ACR/ARP Annual Meeting
Pregnancy Outcomes in Women Exposed to Golimumab
Suzan Esslinger¹, Susan Gabriel ², Marijo Otero-Lobato ³, Michael Clark ⁴, Pamela Sheridan ⁴ and Anja Geldhof ⁵, ¹Janssen Biologics BV, Leiden, Netherlands, ²Janssen Rearch & Development, LLC, Horsham, PA, ³Janssen Biologics BV, Leiden, Zuid-Holland, Netherlands, ⁴Janssen Research & Development, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Leiden, Netherlands
Background/Purpose: Rheumatologic disorders and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic…
Abstract Number: 2369 • 2019 ACR/ARP Annual Meeting
Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Rebecca Overbury¹, Shaobo Pei ², Gopi Penmetsa ³, Brian Sauer ², Vikas Patil ², Jodi Walker ⁴, Jerry Clewell ⁴, Kevin Douglas ⁴, Daniel Clegg ⁵, Grant Cannon ⁶, Ahmad Halwani ⁷ and Jessica Walsh ⁸, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²Division of Epidemiology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ³Gopi K. Penmetsa, MD, Division of Rheumatology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴AbbVie Inc., Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁷Division of Hematology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁸Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Delays in treatment for inflammatory arthritis (IA) are associated with unfavorable outcomes, including impaired quality of life, irreversible joint damage, and disability. Our objective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].